Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Last trade$5.54
Day change+$0.33 (+6.33%)
Day range$5.23 – $6.30
Volume62,222
Market cap$78M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$78.13M
Price / earnings
1.14×
Price / book
1.08×
Price / sales
3.11×
EV / sales
-0.1×
EV / EBITDA
0.29×
Profitability
Earnings per share
$4.59
Return on assets
60.47%
Return on equity
94.89%
Dividend yield
28.77%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.05×
Quick ratio
3.04×
Cash ratio
2.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$987.32K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CPIX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.16M
$166.46K
$9.13M
$13.68M
$171.82K
$380.8K
$11.71M
$10.44M
Cost of revenue
$1.06M
$0
$1.93M
$2.24M
$0
$0
$1.43M
$1.98M
Gross profit
$1.09M
$166.46K
$7.2M
$11.44M
$171.82K
$380.8K
$10.29M
$8.46M
Selling, general and administrative
$2.18M
$2.55M
$7.62M
$10.25M
$2.38M
$2.66M
$6.69M
$7.55M
Research and development
$841.16K
$772.16K
$1.46M
$1.55M
$646.47K
$837.4K
$1.3M
$1.29M
Total operating expenses
$3.03M
$3.33M
$10.33M
$12.81M
$3.03M
$3.5M
$9M
$10.3M
Operating income
-$1.94M
-$3.16M
-$3.13M
-$1.37M
-$2.86M
-$3.12M
$1.29M
-$1.84M
Interest expense
-$4.6K
-$724
-$85.84K
-$112.94K
-$29
-$471
-$163.8K
-$223.26K
Income before taxes
-$1.59M
-$3.1M
-$3.28M
-$1.39M
-$2.72M
-$2.99M
$1.25M
-$1.96M
Income taxes
$3.87K
$3.87K
$3.87K
$23.25K
$5.67K
$5.67K
$5.67K
-$57K
Net income
$77.78M
-$4.27M
-$3.29M
-$1.43M
-$1.95M
-$735.21K
$1.25M
-$1.9M
Net income attributable to common shareholders
$77.78M
-$4.28M
-$3.29M
-$1.41M
-$1.94M
-$740.74K
$1.26M
-$1.9M
EBITDA
-$1.91M
-$4.37M
-$1.85M
-$329.31K
-$2.83M
-$4.07M
$2.32M
-$345.65K
Basic earnings per share
$5.19
-$0.29
-$0.22
-$0.10
-$0.13
-$0.05
$0.08
-$0.14
Diluted earnings per share
$5.07
-$0.29
-$0.22
-$0.10
-$0.13
-$0.05
$0.08
-$0.14
Recent news
Company coverage with links to the original publishers.
Global hepatic encephalopathy market expected to grow steadily, driven by rising liver disease prevalence, improved diagnostics, and novel therapies, despite challenges like high treatment costs and underdiagnosis.
RedHill Biopharma received a Nasdaq Staff Determination letter indicating non-compliance with minimum stockholders' equity requirements. The company plans to appeal the determination and believes its recent transaction with Cumberland Pharmaceuticals has improved its equity position.
The diffuse cutaneous systemic sclerosis (dcSSc) market is evolving towards targeted therapies addressing fibrosis and immune modulation, with promising drug candidates from multiple pharmaceutical companies targeting various pathogenic pathways.
The Duchenne muscular dystrophy market is experiencing steady growth driven by advancements in gene therapies, exon-skipping drugs, and emerging treatment options. Key players are expanding pipelines with novel therapies in late-stage clinical trials, with potential market transformation expected between 2025-2034.
The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 3, 2026
$1.50
Jul 31, 2026
special
Stock splits
Historical share-structure events and their execution dates.